Fresenius Medical Care (NYSE:FMS) Hits New 1-Year High – Still a Buy?

Shares of Fresenius Medical Care AG (NYSE:FMS) reached a new 52-week high on Friday . The company traded as high as $24.35 and last traded at $24.25, with a volume of 248560 shares changing hands. The stock had previously closed at $23.17.

Wall Street Analyst Weigh In

FMS has been the subject of several recent analyst reports. StockNews.com initiated coverage on shares of Fresenius Medical Care in a research note on Friday, January 3rd. They set a “strong-buy” rating for the company. Truist Financial lifted their price objective on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the stock a “hold” rating in a research note on Monday, January 6th. Berenberg Bank initiated coverage on shares of Fresenius Medical Care in a research note on Wednesday, November 6th. They set a “buy” rating and a $25.60 price objective for the company. Finally, Bank of America raised shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd.

Fresenius Medical Care Price Performance

The firm has a market cap of $14.45 billion, a PE ratio of 20.35, a price-to-earnings-growth ratio of 0.75 and a beta of 0.92. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42. The stock has a 50 day moving average price of $22.92 and a two-hundred day moving average price of $21.04.

Fresenius Medical Care (NYSE:FMS) last issued its earnings results on Tuesday, November 5th. The company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.42 by $0.03. The firm had revenue of $5.23 billion for the quarter, compared to analyst estimates of $5.36 billion. Fresenius Medical Care had a return on equity of 6.04% and a net margin of 3.43%. During the same quarter in the prior year, the firm earned $0.31 earnings per share. As a group, equities analysts expect that Fresenius Medical Care AG will post 1.53 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Allworth Financial LP raised its stake in shares of Fresenius Medical Care by 53.1% during the 3rd quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock worth $36,000 after buying an additional 581 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in Fresenius Medical Care in the 3rd quarter valued at $38,000. GAMMA Investing LLC grew its holdings in Fresenius Medical Care by 50.4% in the 3rd quarter. GAMMA Investing LLC now owns 4,998 shares of the company’s stock valued at $106,000 after buying an additional 1,675 shares in the last quarter. ORG Wealth Partners LLC purchased a new position in shares of Fresenius Medical Care during the 3rd quarter worth $112,000. Finally, Venturi Wealth Management LLC grew its holdings in shares of Fresenius Medical Care by 1,045.8% during the 3rd quarter. Venturi Wealth Management LLC now owns 5,259 shares of the company’s stock worth $112,000 after purchasing an additional 4,800 shares during the period. 8.37% of the stock is owned by institutional investors and hedge funds.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.